Table 1.

Summary of Validated Drugs for the Treatment of Advanced HCC in Second Line

	Cabozantinib	Regorafenib	Ramucirumab
Target	VEGFR 1–3, RET, MET, AXL, KIT	VEGFR 1–3, RET, KIT, PDGFR	VEGFR-2
Control arm	Placebo	Placebo	Placebo
OS (months) HR, p value	10.2 vs 8.0 0.76, p = 0.005	10.6 vs 7.8 0.63, p < 0.0001	8.5 vs 7.3 0.71, p = 0.0199
PFS (months) HR, p value	5.2 vs 1.9 0.44, p < 0.001	3.1 vs 1.5 0.46, p < 0.0001	2.8 vs 1.6 0.452, p < 0.0001
ORR	4% vs 0.4%	11% vs 4%	4.6% vs 1%

Note: Data from these studies.^5–7

Abbreviations: VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; OS, overall survival; HR, hazard ratio; PFS, progression-free survival; ORR, objective response rate.